Skip to content
Start free

Divi's Laboratories Ltd.

NSE: DIVISLABHealthcareDrug Manufacturers - Specialty & Generic

Last close
₹9,340.00
Day change
−₹21.00 (−0.22%)vs
Market cap
₹2.46 lakh crIndian rupees
Research updated
1 report
Follow Divi's Laboratories

Share this file

About Divi's Laboratories

Divi's Laboratories Ltd. is an Indian pharmaceutical manufacturing company headquartered in Hyderabad, India, founded in 1990. It specializes in the production of active pharmaceutical ingredients (APIs), intermediates, and nutraceutical ingredients for global innovator and generic drug companies. Divi's Laboratories focuses on generic APIs across diverse therapeutic areas and provides custom synthesis and contract manufacturing services, supporting large pharmaceutical firms throughout the drug development and commercialization lifecycle. The company operates multiple cGMP-compliant manufacturing facilities capable of producing volumes from small kilogram-scale batches to large tonnage supplies for worldwide distribution. Through its nutraceuticals segment, Divi's Laboratories supplies carotenoids, vitamins, and other nutritional ingredients to the pharmaceutical, food and beverage, dietary supplement, and animal feed industries. Serving regulated markets such as the United States and Europe as well as many other countries, Divi's Laboratories plays a significant role as a global API and nutraceutical supplier, enabling customers to secure reliable, high-quality inputs for finished dosage forms and nutrition products.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Listing
NSE: DIVISLAB
Chief executive
Dr. Kiran Satchandra Divi B. Pharm., M.Pharm
Employees
11,565
Headquarters
Hyderabad, India
ISIN
INE361B01024
Website
divislabs.com

Public research

The latest report on Divi's Laboratories opens with Individual or above

Mool’s latest report on Divi's Laboratories, of 2 Oct 2026, has no section published on the open web.

With Individual or above

What the full research on Divi's Laboratories includes

Every piece of Mool’s research is built the same way: a researched evidence base, analyses that build on each other, a research model and a report with the call.

The report and Mool’s call

  • The 12-month rating and target
  • The 3-month view
  • Mool's estimates beside the street's
  • The claims the view rests on, and what would change it

The analyses, among them

  • Business model & financial foundationWhat the company does and how it makes money, its structure, five years of financials and the metrics that matter for it.
  • Future earnings & financial modelForecasts built from the drivers that move the business, by scenario, beside the street's.
  • Fundamental valuation & 12-month thesisWhat the business is worth on several methods, what the market already prices in and the 12-month thesis that follows.

The research model

The model behind the report: the company’s history, the drivers that move it, its forecasts by scenario and the valuation the 12-month target comes from.

See Mool’s call and the full research

Individual or above opens every piece of research Mool has published. A new account can start with 10 days of Pro, or of Firm on a work email address. No card needed.

Report history

Reports on Divi's Laboratories

  1. Research reportLatest

Same sector

All Healthcare companies

  • Sun Pharmaceutical Industries Ltd.

    NSE: SUNPHARMA

    Healthcare · Drug Manufacturers - Specialty & Generic

    ₹1,760.00 last close on 9 Oct 2026 +0.01%

    Research updated

  • Torrent Pharmaceuticals Ltd.

    NSE: TORNTPHARM

    Healthcare · Drug Manufacturers - Specialty & Generic

    ₹4,656.90 last close on 9 Oct 2026 +0.86%

    Research updated

  • Zydus Lifesciences Ltd.

    NSE: ZYDUSLIFE

    Healthcare · Drug Manufacturers - Specialty & Generic

    ₹1,117.50 last close on 9 Oct 2026 +0.49%

    Research updated

  • Lenskart Solutions Limited

    NSE: LENSKART

    Healthcare · Medical Instruments & Supplies

    ₹677.65 last close on 9 Oct 2026 +3.62%

    Research updated

  • Emcure Pharmaceuticals Ltd.

    NSE: EMCURE

    Healthcare · Drug Manufacturers - Specialty & Generic

    ₹1,833.50 last close on 9 Oct 2026 −0.97%

    Research updated

Prices are the last close on the NSE, 9 Oct 2026. Research from Mool’s report of 2 Oct 2026; page updated 12 Oct 2026.

Mool’s research is written by AI agents and published by Mool Capital Private Limited, a SEBI-registered Research Analyst, registration INH000012449, which is responsible for it. This page shows factual company information; it carries no rating and is not investment advice for any individual. Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Read the disclosures.